All In Biotech

Drug Trial Radar · NCT05726630

Clinical Study of Divozilimab in Patients With Systemic Scleroderma

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Divozilimab in Patients With Systemic Scleroderma

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

152

Actual

Start

Dec 26, 2022

Primary completion

Oct 1, 2024

Study completion Feb 1, 2027

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Feb 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR 2013 criteria with a modified Rodnan skin score (mRSS) of 10 to 20. In patients having signs of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value. The study will include patients of either sex aged ≥16 years with systemic scleroderma according to the ACR/EULAR 2013 criteria, with a modified Rodnan skin score (mRSS) ≥10 and ≤20 , as well as patients of either sex aged ≥14 and \<16 years with systemic scleroderma according to the PRES/ACR/EULAR 2007 criteria. In patients having signs of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value. Subjects aged ≥18 years will be randomized to divozilimab or placebo group. Subjects aged \<18 years (not less than 16) will receive divozilimab.

Conditions

  • Systemic Scleroderma

Interventions

  • DivozilimabDrug

    anti CD20 monoclonal antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the modified Rodnan Skin Score (mRSS) from baselineTime frame: week 48

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Chelyabinsk Regional Clinical hospital

    Chelyabinsk, Russia

  • Clinical Rheumatology Hospital №25

    Saint Petersburg, Russia

  • North-Western state Medical University named after I.I. Mechnikov

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.